Catalog No.
Product Name
Application
Product Information
Citations
-
CerS6 Inhibitor, Ceramide Synthesis Inhibitor, Acetylcholinesterase Inhibitor
FF-C1 is a non-competitive inhibitor of Ceramide Synthase 6 (CerS6), exhibiting an IC50 of 7.89 μM. By inhibiting intestinal CerS6, FF-C1 effectively lowers serum ceramide levels, offering protective effects against metabolic dysfunction-associated steatohepatitis. This compound is also reported to inhibit acetylcholinesterase, highlighting its potential applications in studying metabolic disorders and neurodegenerative diseases. -
Endogenous Metabolite
4-Chloro-N,N-diisopropylbenzamide is an amide with significant relevance as a substrate for cytochrome P450 enzymes in vivo and for acetylcholinesterase in vitro. This compound plays a crucial role in metabolic studies, enabling the investigation of enzyme kinetics and substrate specificity. Its application extends to research focused on drug metabolism and neuropharmacology. -
Endogenous Metabolite
Tetrachlorvinphos is an organophosphorus compound that primarily acts as a cholinesterase inhibitor. This metabolite is commonly utilized in agricultural settings for pest control due to its effectiveness against a variety of insects. With low toxicity to mammals, tetrachlorvinphos serves as a useful tool for studying pesticide interactions and their effects on non-target organisms. -
Stable Isotope
(Z)-Tetrachlorvinphos-d6 is a deuterated form of Tetrachlorvinphos, an organophosphorus pesticide that primarily acts as a cholinesterase inhibitor. This stable isotope is utilized in research to trace metabolic pathways and analyze pesticide residues in various biological matrices. With low toxicity to mammals, it provides a safe and useful tool for studying the environmental impact and biochemical interactions of pesticide application. -
Endogenous Metabolite
Bendiocarb is a carbamate compound that primarily acts as an inhibitor of the enzyme acetylcholinesterase. This inhibition results in increased levels of acetylcholine, which plays a crucial role in neurotransmission and muscle contraction. Bendiocarb is utilized in research applications focusing on neurobiology and the study of cholinergic systems, as well as in the examination of potential neurotoxic effects. -
Endogenous Metabolite
Neostigmine iodide is a reversible inhibitor of acetylcholinesterase, enhancing muscle tone and function. This compound is primarily utilized in the management of myasthenia gravis, aiming to improve muscle strength in affected patients. Additionally, Neostigmine iodide is employed in anesthetic procedures to counteract the effects of nondepolarizing muscle relaxants, such as rocuronium, thereby facilitating recovery from anesthesia. -
Endogenous Metabolite
BuChE-IN-14 is a selective inhibitor of acetylcholinesterase (AChE), primarily targeting endogenous metabolite pathways. In vitro studies demonstrated a concentration-dependent inhibition of AChE activity in rat brain tissue, leading to increased extracellular acetylcholine (ACh) levels in the hippocampus and striatum. This compound shows potential for addressing memory impairments linked to cholinergic dysfunction, making it valuable for research into neurodegenerative diseases and cognitive enhancement. -
Methyltransferase
Catechol O-methyltransferase (COMT), derived from porcine liver, is a methyltransferase that facilitates the magnesium-dependent transfer of methyl groups from S-adenosyl methionine to the hydroxyl group of dopamine, resulting in the formation of 3-methoxytyramine. This enzyme exists in two forms: a soluble form (S-COMT) and a membrane-bound form (MB-COMT). COMT plays a critical role in regulating the levels of key neurotransmitters, including epinephrine, norepinephrine, and dopamine, making it essential for research related to neuropharmacology and psychiatric disorders. -
Isotope-Labeled Compounds
(±) Anabasine-d4 is a deuterated analog of (±) Anabasine, serving as a useful isotope-labeled compound. This racemic mixture acts as an agonist of the α7 nicotinic acetylcholine receptor (α7nAChR), demonstrating notable anti-inflammatory properties and insecticidal activity. It is suitable for applications in pharmacological research, particularly studies involving receptor activation and inflammatory responses. -
Cholinesterase (ChE) Inhibitor
Vomifoliol is a cholinesterase (ChE) inhibitor that exhibits significant antiacetylcholinesterase activity, comparable to that of abscisic acid (ABA). Additionally, this compound shows moderate antileishmanial activity, making it a valuable tool for research into neurodegenerative disorders and parasitic infections. Its unique structure, featuring a modified 2,4-pentadiene side chain, further contributes to its biological activity, offering potential applications in pharmacological studies. -
Acetylcholinesterase Inhibitor
Trimethylammonium chloride is a non-competitive inhibitor of acetylcholinesterase, targeting the enzymatic activity responsible for the hydrolysis of the neurotransmitter acetylcholine. By reversibly blocking the deacetylation process of acetylcholinesterase, this reagent plays a critical role in studies related to neurobiology and the modulation of synaptic transmission. Its application extends to research investigating cholinergic signaling pathways and potential therapeutic strategies for neurological disorders. -
Racemate of Anabasine
(±) Anabasine is the racemic mixture of Anabasine, acting as an agonist of the alpha-7 nicotinic acetylcholine receptor (α7nAChR). This compound has demonstrated anti-inflammatory properties and insecticidal activity, making it relevant for research in neuropharmacology and pest control studies. Its biological activities encourage further investigations into its therapeutic potential and applications. -
Ligand for Target Protein for PROTAC
Aberrant tau ligand 1 is a specific ligand targeting abnormal tau proteins. This compound facilitates the development of proteolysis-targeting chimeras (PROTACs) designed for the degradation of aberrant tau, enabling research into tau-related pathologies. It is a valuable tool for studying tau protein dynamics and their implications in neurodegenerative diseases. -
Monoamine Oxidase Inhibitor
MAO-B-IN-2 is a selective and competitive inhibitor of monoamine oxidase B (MAO-B) with an IC50 value of 0.51 μM, and it also inhibits butyrylcholinesterase (BChE) with an IC50 of 7.00 μM. This compound plays a significant role in studying neurodegenerative disorders by modulating monoamine metabolism, making it valuable for research into conditions such as Parkinson's disease and Alzheimer's disease. Its specificity for MAO-B makes it an important tool for exploring therapeutic pathways involving neurotransmitter regulation. -
O-GlcNAcase Inhibitor
O-GlcNAcase-IN-5 is a selective inhibitor of O-GlcNAcase, a key enzyme involved in the removal of O-GlcNAc modifications from proteins. By inhibiting this enzyme, O-GlcNAcase-IN-5 effectively prevents the deacetylation of tau protein, thereby reducing its excessive phosphorylation. This compound is particularly relevant for research in Alzheimer's disease and other neurodegenerative conditions where tau protein modification plays a critical role. -
OGT Inhibitor
OGT-IN-1 is a selective inhibitor of O-GlcNAc transferase (OGT), with IC50 values of 27 μM for soluble OGT (sOGT) and 10 μM for nuclear OGT (ncOGT). This compound plays a crucial role in regulating protein O-GlcNAcylation, thereby influencing various cellular processes such as signal transduction and gene expression. OGT-IN-1 is valuable for research applications focused on studying OGT-related metabolic disorders, cancer biology, and neurodegenerative diseases. -
OGT Inhibitor
PG 34 is a selective inhibitor of O-GlcNAc transferase (OGT), exhibiting an IC50 value of 68 μM. This compound targets the OGT enzyme, playing a crucial role in the regulation of O-GlcNAcylation. PG 34 is primarily applied in studies of cellular signaling, metabolic processes, and glycosylation-related research, offering insights into the role of OGT in various biological contexts. -
OGT Inhibitor
OGT-IN-4 is a potent inhibitor of O-GlcNAc transferase (OGT), displaying a dissociation constant (Kd) of 8 nM. This compound is valuable for investigating the role of OGT in various biological processes and diseases, including metabolic disorders and cancer. Its specificity makes OGT-IN-4 a useful tool for researchers studying O-GlcNAcylation and its impact on cellular signaling pathways. -
OGT Inhibitor
BZX2 is an irreversible covalent inhibitor of O-GlcNAc transferase (OGT), demonstrating an IC50 of less than 10 µM. This compound is cell-permeable, allowing for effective intracellular delivery, though it may exhibit multiple off-target effects. BZX2 is primarily utilized in research applications focused on OGT-related signaling pathways and O-GlcNAcylation processes in various biological contexts. -
α-Synuclein/Tau Degrader
PROTAC α-Synuclein/Tau degrader 1 targets α-synuclein and tau for degradation through the ubiquitin-proteasome system. This dual PROTAC degrader demonstrates effective binding with dissociation constants of 0.47 μM and 2.78 μM for α-synuclein and tau, respectively, and has DC50 values of 1.57 μM and 4.09 μM. Its ability to penetrate the blood-brain barrier makes it a valuable tool for research into neurodegenerative diseases, particularly Parkinson's disease. The compound's design includes components for ligand binding and a linker optimized for efficient degradation. -
TTBK1 Inhibitor
TTBK1-IN-1 is a selective inhibitor of tau tubulin kinase 1 (TTBK1), exhibiting an impressive IC50 of 2.7 nM. This compound demonstrates significant potential for the investigation of Alzheimer's disease and associated tauopathies. Additionally, TTBK1-IN-1 features an alkyne functional group, enabling it to participate in copper-catalyzed azide-alkyne cycloaddition (CuAAc), making it a valuable tool for click chemistry applications in biological research. -
PET Tracer
PBB3 is a positron emission tomography (PET) tracer that targets tau protein accumulation. It is utilized in the detection and quantification of tau levels in neurodegenerative diseases, including Alzheimer's disease as well as other tauopathies. PBB3 serves as a valuable tool in research aimed at understanding tau pathology and its implications in cognitive decline. -
Tau-lowering Antisense Oligonucleotide
Diranersen is a Tau-lowering antisense oligonucleotide designed to target and inhibit tau protein expression. This compound holds potential for advancing research in Alzheimer’s disease and related neurodegenerative conditions. By reducing tau levels, Diranersen aims to facilitate studies focused on tau pathology and its implications in Alzheimer's progression. -
TTBK1 Inhibitor
TTBK1-IN-2 is a selective inhibitor of Tau-Tubulin kinase 1 (TTBK1), exhibiting IC50 values of 0.24 µM and 4.22 µM. This compound demonstrates significant brain penetration in vivo and effectively reduces TDP-43 phosphorylation in both cell culture models and the spinal cord of transgenic TDP-43 mice. TTBK1-IN-2 is valuable for research focused on neurodegenerative diseases, particularly those associated with TDP-43 pathology. -
Tau and α-syn Inhibitor
MG-2119 is a potent inhibitor of tau and α-synuclein aggregation, primarily acting on the monomeric forms of these proteins. This compound demonstrates significant potential in the study of neurological disorders, making it a valuable tool for researchers investigating the pathophysiology of tauopathies and synucleinopathies. Its inhibitory effects on protein aggregation could provide insights into therapeutic strategies for related neurodegenerative diseases. -
Tau Fibrils Decomposing Agent
CNS-11 is a tau fibril-degrading agent that effectively penetrates the blood-brain barrier. This compound demonstrates the ability to reduce α-synuclein levels, making it a valuable tool in the study of neurodegenerative disorders. CNS-11 is applicable in research focused on Alzheimer's and Parkinson's diseases, contributing to the understanding of tau pathology and its implications in these conditions. -
Tau Ligand
Florzolotau is a tau ligand designed for positron emission tomography (PET) imaging, targeting the β-sheet region of paired helical filaments (PHFs) and straight filaments (SFs) of tau protein. Its binding affinity extends to intraneuronal inclusions present in Alzheimer's disease, primary age-related tauopathy, and posterior cortical atrophy. This compound shows significant potential in the diagnosis and study of tau proteinopathies, facilitating improved imaging of neurological disorders associated with tau aggregation. -
Secreted Clusterin Enhancer
DDL-357 is a potent enhancer of secreted clusterin, targeting key pathways involved in neurodegenerative processes. It effectively reduces levels of phosphorylated tau in the brain, contributing to memory improvement in the murine 3xTg-AD model. This compound is a valuable tool for researching therapeutic strategies in Alzheimer's disease and related cognitive disorders. -
Tau Aggregation Inhibitor
BSc3094 acts as a Tau aggregation inhibitor, targeting the pathological accumulation of tau protein implicated in neurodegenerative diseases. This compound has shown potential in research focused on Alzheimer's disease, making it a valuable tool for studying tau-related mechanisms and therapeutic interventions for neurodegeneration. -
Tau Protein Inhibitor
NQTrp is a potent inhibitor of tau protein aggregation, functioning primarily through its interaction with amyloidogenic structures. This naphthoquinone-tryptophan hybrid exhibits significant anti-amyloidogenic properties, effectively inhibiting the in vitro aggregation of hexapeptide 41GCWMLY46, located in the N-terminus of γD-crystallin, as well as the full-length γD-crystallin. NQTrp is a valuable reagent for research applications focusing on neurodegenerative disorders, particularly those associated with tau pathology. -
Tau Ligand
Tau Ligand-1 is a specific ligand that targets aggregated tau protein and is capable of crossing the blood-brain barrier. Demonstrating high affinity for aggregated tau in brain tissues from Alzheimer's disease and other tauopathies, it displays equilibrium dissociation constant (KD) values between 1 and 3.8 nM. This compound shows potential as a positron emission tomography (PET) tracer, offering valuable applications in imaging studies related to tau-associated neurodegenerative diseases in the central nervous system. -
Tau Aggregation Inhibitor
TAU-IN-4 is a potent inhibitor of tau aggregation, demonstrating a KD of 1.58 μM. This compound is primarily utilized in research focused on Alzheimer's disease, where it aids in the exploration of tau-related pathophysiological mechanisms. Its capability to inhibit tau aggregation makes it a valuable tool for studying neurodegenerative processes and potential therapeutic interventions. -
DYRK1A Inhibitor
ZJCK-6-46 is a potent DYRK1A inhibitor, demonstrating an IC50 of 0.68 nM. This compound exhibits high blood-brain barrier permeability, making it suitable for central nervous system applications. ZJCK-6-46 effectively reduces tau phosphorylation, contributing to the amelioration of cognitive dysfunction by decreasing phosphorylated tau levels and mitigating neuronal loss in vivo. Its biological activity positions it as a valuable tool for researching neurodegenerative diseases. -
Tau Protein Aggregation Inhibitor
Tau protein aggregation-IN-1 is an inhibitor of Tau protein aggregation. It has demonstrated significant potential in the study of neurodegenerative disorders associated with protein misfolding, including Alzheimer's disease, dementia, Parkinson's disease, Huntington's disease, and prion-induced spongiform encephalopathies. This compound is essential for researchers investigating the mechanisms of Tau pathology and the development of therapeutic strategies targeting aggregated proteins. -
THK5351 R enantiomer
THK5351 (R enantiomer) is a selective ligand for the translocator protein (TSPO), which is involved in neuroinflammation. This compound exhibits high affinity for TSPO and is utilized in research related to neurodegenerative diseases, allowing for the visualization of neuroinflammatory processes in vivo. THK5351 (R enantiomer) serves as an invaluable tool in studying the role of inflammation in the pathogenesis of disorders such as Alzheimer's disease and other neurodegenerative conditions. -
THK5351 R enantiomer
THK5351 is a selective radiolabeled ligand targeting tau pathology in the brain. This compound serves as a radiotracer for in vivo imaging, facilitating the study of tau-related neurodegenerative diseases such as Alzheimer's. The application of THK5351 in research enables the visualization and quantification of tau aggregation, providing essential insights into disease progression and potential therapeutic interventions. -
Tau fragment R2
Tau Peptide (275-305) targets the second repeat domain of the tau protein, which plays a critical role in microtubule binding and is implicated in Alzheimer's disease. This peptide specifically interacts with group IIB metal ions (Zn²⁺, Cd²⁺, Hg²⁺), facilitating conformational changes and promoting pathological accumulation. Research applications include investigating the effects of heavy metals on tau protein dynamics and their contributions to neurodegenerative disease mechanisms. -
TTBK1/2 Inhibitor
TTBK1/2-IN-3 is a selective inhibitor of tau tubulin kinase 1 (TTBK1) and TTBK2, demonstrating IC50 values of 579 nM and 258 nM, respectively. This compound inhibits TDP-43 phosphorylation, thereby influencing protein aggregation pathways associated with neurodegenerative diseases. Additionally, TTBK1/2-IN-3 has been shown to reduce the expression of primary cilia on the surface of induced pluripotent stem cells (iPSCs), making it a valuable tool for research into cellular signaling and neurodegeneration. -
Tau Fragment
Tau Peptide (273-284) is a truncated fragment of the Tau protein, primarily involved in neurofibrillary tangles associated with tauopathies. This peptide is valuable for studying the molecular mechanisms of Alzheimer's disease and other related neurodegenerative disorders. It serves as a tool for elucidating Tau aggregation processes and investigating potential therapeutic interventions targeting Tau-related pathologies. -
Tau Protein
JG-23 is a 4-chloro modified analog that effectively promotes the degradation of tau protein. Demonstrating good metabolic stability, JG-23 has a half-life of 36 minutes in mouse liver microsome assays. This compound is valuable for research focused on tau-related neurodegenerative diseases and the underlying mechanisms of tau protein regulation. -
TTBK1/TTBK2 Inhibitor
AMG28 is a selective inhibitor of Tau tubulin kinase 1 (TTBK1) and TTBK2, with IC50 values of 805 nM and 988 nM, respectively. This compound effectively inhibits tau phosphorylation at Ser422, demonstrating an IC50 of 1.85 μM. AMG28 is primarily utilized in research investigating tau-related pathologies and neurodegenerative disorders. -
Polypeptide
Tau Peptide (255-314) (Repeat 2 Domain) (human) is a polypeptide derived from the Tau-F protein, specifically the 255-314 fragment of this key isoform. This peptide encompasses critical aggregation sequences PHF6* (275-280, VQIINK) and PHF6 (306-311, VQIVYK), which play a significant role in Tau aggregation. It spans the C-terminal half of the repeat domain R1, the entire repeat domain R2, and the N-terminal half of repeat domain R3, making it vital for studies on Tau-related neurodegenerative processes and microtubule dynamics. -
MAPT Splicing Modulator
PTC-700 is a potent modulator of microtubule-associated protein tau (MAPT) splicing. This compound effectively reduces 4-repeat isoform MAPT levels in P301L and S305N neuronal models, exhibiting EC50 values of 1.3-1.8 nM and 0.5-2.6 nM, respectively. PTC-700 is utilized in research applications focused on tauopathies and neurodegenerative disorders, contributing to the understanding of tau protein dynamics and potential therapeutic avenues. -
TTBK1 Inhibitor
(R)-TTBK1-IN-1 is a selective inhibitor of tau tubulin kinase 1 (TTBK1), demonstrating potent activity in targeting this enzyme. Its brain-penetrant properties make it particularly useful for studying Alzheimer's disease and related tauopathies. Additionally, (R)-TTBK1-IN-1 is equipped with an alkyne group, facilitating click chemistry applications through copper-catalyzed azide-alkyne cycloaddition (CuAAc) for further biochemical research. -
Tau Ligand
T808 is a selective ligand targeting tau protein, crucial in Alzheimer's disease research. This compound can be utilized to synthesize [18F]-T808, a highly selective tau protein positron emission tomography (PET) tracer, facilitating in vivo imaging studies. Additionally, T808 serves in the synthesis of [3H]-T808, a radioactive marker suitable for in vitro experiments, further advancing our understanding of tau-related pathologies. -
tau Protein Inhibitor
Sabeluzole (R 58735) serves as a tau protein inhibitor, demonstrating significant neuroprotective effects. This benzothiazol derivative exhibits antiischemic, antiepileptic, and cognitive-enhancing properties by mitigating NMDA- and glutamate-induced neurotoxicity through the inhibition of tau expression. Additionally, Sabeluzole has been shown to enhance memory in animal models and counters the amnesic effects of Chlordiazepoxide. Its applications extend to research on Alzheimer's disease, making it a valuable tool for investigating tau-related neurodegenerative mechanisms. -
TAU Inhibitor
TAU-IN-1 is a selective inhibitor of TAU protein with an EC50 value of 325 nM. This compound is primarily utilized in research focused on neurodegenerative diseases, particularly those related to tau pathology. Its ability to modulate Tau protein activity makes it a valuable tool for investigating mechanisms of neurodegeneration and potential therapeutic interventions. -
Tau Fibril Binding Agent
BF-170 is a selective tau fibril binding agent that targets tau protein aggregates, exhibiting an EC50 of 221 nM. It demonstrates effective blood-brain barrier permeability, with brain tissue concentrations reaching 9.1% ID/g within 2 minutes post intravenous administration in mice. BF-170 serves as a valuable tool for imaging tau pathology associated with Alzheimer's disease and is instrumental in early-stage AD research, offering potential for studies focused on tau-related neurodegenerative disorders. -
Tau fragment
Tau Peptide (244-274) targets the Repeat 1 domain of the tau protein, a key player in neurodegenerative diseases such as Alzheimer's. This peptide fragment is commonly utilized in research to study tau pathology, including phosphorylation and aggregation processes associated with tau-mediated toxicity. Its role in modulating tau interactions makes it a valuable tool for investigating tau-related mechanisms in various cellular models. -
Tau Ligand
Aberrant tau ligand 2 (Compound 4-12) selectively targets the tau protein, serving as a crucial ligand in research on tau pathology. This compound plays an essential role in the development of PROTAC degraders, specifically for the synthesis of C004019, facilitating studies on tau-related neurodegenerative diseases. Its application in the exploration of targeted protein degradation highlights its significance in advancing therapeutic strategies.
